The influence of pyrene-fatty acids on the resistance of cells to ultraviolet (UV) radiation was investigated in cultured fibroblasts from patients with five types of peroxisomal disorders. All showed reduced survival compared to control. The effect varied with the biochemical defect involved and the chain length of the pyrene fatty acid. Reduced survival was observed in cells deficient in plasmalogens (rhizomelic chondrodysplasia punctata) and in cells deficient in peroxisomal fatty acid oxidation (bifunctional enzyme deficiency), which accumulated pyrene-fatty acids. X-linked adrenoleukodystrophy fibroblasts accumulated pyrene-fatty acids and showed increased UV sensitivity only when exposed to longer-chain pyrene fatty acids. UV radiation resistance was lowest in cells with combined impairment of plasmalogen synthesis and fatty acid oxidation (Zellweger syndrome, neonatal adrenoleukodystrophy), suggesting that UV sensitivity correlates inversely with the ratio of plasmalogens to radical producing substances.
Introduction
The peroxisomal disorders Zellweger syndrome (ZS)' and rhizomelic chondrodysplasia punctata (RCDP) are associated with malformations of multiple organs and lead to early death.
Although ZS was formerly assigned to the "multiple congenital anomaly" disease category (1) , it is now generally accepted that the basic abnormality is the failure to form normal peroxisomes (2) . Multiple peroxisomal functions are defective, including the formation of plasmalogens and certain bile acids, and the oxidation ofvery long chain fatty acids (VLCFA), phytanic acid, and pipecolic acid. RCDP has also been shown to be a peroxisomal disorder (3, 4) , but the defect is more restricted since the organelle is formed, and peroxisomal malfunctions are confined to defective synthesis of plasmalogens, phytanic acid oxidation, and the processing of one of the peroxisomal enzymes, 3-oxoacyl-coenzyme A thiolase.
There is as yet no information about the mechanisms by which peroxisomal malfunction leads to the profound disturbances associated with ZS and RCDP. The accumulations of VLCFA and bile acid intermediates probably play a role since multiple malformations, including those ofthe brain, are common to ZS and certain peroxisomal disorders in which biochemical defects are confined to VLCFA and bile acid metabolism (5, 6) . Instead it is the defects ofplasmalogen synthesis and phytanic acid oxidation that represent a point of commonality between ZS and RCDP.
An important potential pathogenetic mechanism was suggested by a recent report of Zoeller et al. (7) in their studies of Chinese hamster ovary cells that lack peroxisomes and demonstrate the broad array of biochemical defects characteristic of ZS (8) . When those cells were cultivated in the presence of the photosensitizer 12-(l'-pyrene)dodecanoic acid (P12), they were more sensitive to ultraviolet (UV) irradiation than normal cells. This hypersensitivity has been attributed to the lack of protection against singlet oxygen or radicals produced by P12. Singlet oxygen and radicals can cause extensive damage to lipids, proteins, and nucleic acids (9) . Such damage could be a plausible explanation for the multiple malformations associated with human peroxisomal disorders. In this article we demonstrate that cell lines from patients with peroxisomal disorders also show increased sensitivity to pyrene fatty acid (PFA)-mediated UV damage. By comparing this sensitivity in human mutants with different biochemical lesions, such as ZS, RCDP, and isolated defects of peroxisomal ,8-oxidation of VLCFAs, we were able to focus specifically on the role ofplasmalogen deficiency.
Methods
Materials and general methods. 64-1'-Pyrene)hexanoic acid (P6), 10-(1'-pyrene)decanoic acid (P10), and P12 were purchased from Lambda Probes, Graz, Austria. 164-1'-Pyrene)hexadecanoic acid (P16) was obtained from Molecular Probes Inc., Junction City, OR. 1-0-hexadecylsn-glycerol was kindly provided by F. Paltauf, Technical University of decanoic acid; RCDP, rhizomelic chondrodysplasia punctata; UV, ultraviolet; VLCFA, very long chain fatty acid; X-ALD, X-linked adrenoleukodystrophy; ZS, Zellweger syndrome.
Graz. All other chemicals were of analytical grade and obtained from commercial sources.
Cells and culture conditions. Fibroblasts were obtained for diagnostic purposes at the Kennedy Institute. Diagnosis was based on the following biochemical criteria: VLCFAs (10) and phytanic acid (1 1) in serum, oxidation of VLCFAs in fibroblasts (4), plasmalogen biosynthesis in cultured fibroblasts ( 12) , accumulation of bile acid intermediates ( 13) and pipecolic acid ( 14) in serum, subcellular distribution of catalase (15) , and, in some cases, immunoblot analysis of peroxisomal IBoxidation enzymes in liver homogenates and fibroblasts (6) . The patients with ZS and neonatal adrenoleukodystrophy (NALD) belong to complementation groups 1, 2, and 3 described in Roscher et al. (16) . The patient diagnosed as RCDP is case 2 in Hoefler et al. (4) . A patient with a deficiency of peroxisomal bifunctional enzyme was reported by Watkins et al. (6) , and a female patient with an unidentified defect of VLCFA oxidation (f3-ox-def) by Naidu et al. (17) .
All cell lines were cultured at 370C, in a 5% C02, 95% air atmosphere in minimal essential medium (MEM) with Earle's salts supplemented with fetal bovine serum (10% vol/vol), glutamine (I mM), penicillin G (10,000 IU/liter), and streptomycin (0.1 g/liter). PFA were prepared as a 10 mM stock solution in dimethyl sulfoxide and mixed into MEM to obtain the desired concentrations (PFA-MEM). Subcellularfractionation offibroblasts. Approximately 2 x 1O6 cells were incubated with media supplemented with 10 AM P12 for 16 h, washed as described above, and harvested by trypsinization. They were homogenized in a ball-bearing homogenizer and fractionated on a linear gradient ofincreasing (from 15% to 40%) Nycodenz (Sigma Chemical Co., St. Louis, MO) and decreasing (from 0.25 to 0 M) sucrose concentration essentially as described (6) , except that a VTI.80 rotor (Beckman Instruments, Inc., Palo Alto, CA) was used and 15 fractions of 330 Ml each were collected. 100 Ml each was used for determination of fluorescence as described above.
Gelfiltration on Sepharose 4B. Fractions obtained from Nycodenz gradients were loaded onto a column (0.5 X 5 cm) of Sepharose 4B (Pharmacia, Uppsala, Sweden) equilibrated with 0.25 M sucrose containing 10 mM Tris/HCI, pH 7.5, 1 mM EDTA. Fractions of 100 Ml were collected and the fluorescence was measured as described above. Hexadecylglycerol (HDG) supplementation. To increase the plasmalogen content in fibroblasts deficient in peroxisomal plasmalogen biosynthesis, cells were incubated with 60MM HDG for 24 h according to Hermetter et al. (20) before P12 incubation and UV irradiation.
Cellfusion. Parental cell lines were seeded in a 25-cm2 flask in a 1:1 ratio and fused as reported previously (13), except that the separation offusion products from unfused cells was omitted. 4 
Results
Increased sensitivity offibroblastsfrom patients with peroxisomal disorders to P12-UV treatment. Fibroblasts from patients with ZS, NALD, X-linked adrenoleukodystrophy (X-ALD), RCDP, bifunctional enzyme deficiency, and f3-ox-def were incubated in MEM supplemented with P12 at concentrations from 2.5 to 12.5 MM for 24 h. After replacement with normal MEM cells were UV-irradiated for 5 min and the number of surviving cells was determined (Fig. 1 c) . At concentrations of 5 MM < 5% of fibroblasts from patients with ZS, NALD, and bifunctional enzyme deficiency survived, whereas 60% of control and X-ALD cells were still viable. Cells from a patient with RCDP were slightly less affected but clearly more sensitive than controls. At a concentration of 2.5 MM only cells from ZS were affected, but not other cell lines. Concentrations up to 20 M without UV irradiation did not affect cell viability. UV irradiation alone decreased the number of surviving cells by about 10% (data not shown).
Increased sensitivity ofX-ALDfibroblasts to P16-UV treatment. Fibroblasts from patients with ZS, NALD, X-ALD, RCDP, and f3-ox-def were incubated in MEM supplemented with P16 at concentrations ranging from 5 to 15 AM for 24 h and subjected to the standard UV irradiation protocol (Fig. 1  d) . In contrast to the results with P12, cells from patients with X-ALD and fl-ox-def showed increased sensitivity to this treatment. At 7.5 and 12.5 MM < 10% of the cells were viable as compared to 55% and 35% of controls.
To demonstrate the reproducibility of this method and to account for possible variations among different cell lines and passage numbers, fibroblasts from three patients with X-ALD and three controls were measured in duplicate and mean and standard deviation were determined (Fig. 2) . At concentrations of 7.5 and 12.5 gM a clear difference between control and disease cells was observed.
Chain-length specificity ofperoxisomal oxidation ofPFA.
In order to determine the chain length of PFAs that require peroxisomal p3-oxidation, fibroblasts from patients with ZS, bifunctional enzyme deficiency, and RCDP and controls were incubated in media containing 7.5 and 12.5 ,uM ofP6 (Fig. 1 a) and PI0 (Fig. 1 b) Accumulation ofPFAs in fibroblastsfrom patients with defectiveperoxisomal #-oxidation. Intracellular content ofP12 in cells from a patient with ZS and a control was compared using fluorescence microscopy (Fig. 3) . After a 24-h incubation with P12, fibroblasts showed an accumulation of fluorescent material in a distinct punctate pattern. It was more pronounced in ZS and did not match to the staining pattern obtained with antibodies against mitochondria or Golgi apparatus.
To quantify the incorporation of P6, PI0, P12, and P16 into fibroblasts from patients with ZS, NALD, X-ALD, RCDP, and fl-ox-def and controls, fluorescence was measured after incubation with PFAs for 24 h at concentrations indicated (Fig.  4) . Virtually no differences in the incorporation of P6 into cells could be found (data not shown). Cells from patients with ZS and NALD accumulated two to five times more Pl0 (Fig. 4 a) and P1 2 (Fig. 4 b) than controls, X-ALD, RCDP, and fl-ox-def.
For P16 (Fig. 4 c) the intracellular accumulation was less pronounced than for PlO and P12 (50-150% over controls). In contrast to PI0 and P12 however, P16 was stored in fibroblasts from patients with X-ALD and fl-ox-def. Intracellular concentrations of all PFAs in RCDP fibroblasts were comparable to controls.
Incorporation of P12 into different lipid classes were similar in ZS, bifunctional enzyme deficiency, and control (Table I) with the exception that the percentage ofunesterified PFAs was slightly higher~in the fl-oxidation-deficient fibroblasts.
Subcellular localization of PFA incorporated into fibroblasts. To investigate the subcellular distribution ofPFA, fibroblasts from control and a patient with ZS were incubated with 10 gM P 12 for 16 h. After extensive washes they were homogenized and fractionated on a continuous Nycodenz gradient.
49% (control) and 48% (ZS) of the fluorescence label was localized in the two fractions with least density (cytosolic fractions).
The remaining portion was distributed evenly over the gradient and no association with other marker enzymes was found. The two topmost fractions were pooled and analyzed on a Sepharose 4B gel filtration column, which has an exclusion limit of 2 x I07 mol wt for globular proteins. 82% ofthe fluorescence label was recovered in the void volume.
Supplementation with HDG. Peroxisomal steps of plasmalogen biosynthesis can be bypassed by feeding cells with HDG (20) . Accordingly, the plasmalogens can be raised to near normal levels in RCDP and ZS fibroblasts despite their peroxisomal dysfunction of plasmalogen biosynthesis. Thus we were able to discriminate between the effects of an increased exposure to free radicals after UV irradiation in the presence of PFAs and the possible function of plasmalogens in protecting them against these noxes. Cultures were supplemented with HDG and subjected to UV irradiation after incubation with P12 (Fig. 5) . Fibroblasts from patients with RCDP gained a resistance comparable to controls whereas there was no change in the f3-oxidation-deficient cell mutants, ZS and X-ALD. Similarly HDG did not affect the resistance ofcontrol fibroblasts to the PI 2-UV treatment (data not shown).
Normal resistance of heterokaryotic X-ALD/ZS cells to PFA-UV treatment. Among cell lines from patients with disorders of peroxisome biogenesis, five different complementation groups, which were characterized by a normalization of plasmalogen biosynthesis in multikaryotic cells upon successful genetic complementation, could be described by our group (16) .
In order to test the possibility that PFA-UV treatment could provide a method of selecting for biochemically normal cells in p3-oxidation or plasmalogen-deficient mutants, we fused cell lines from different complementation groups. The resulting mixture of monokaryotic and multikaryotic cells was subjected to PFA-UV treatment. For example, without receiving the treatment -10% of cells had two or more nuclei after fusion of fibroblasts from patients ZS1 (complementation group 1) and ZS2 (complementation group 2). With increasing concentrations of P12, the proportion of multikaryotic cells rose to > 50% after UV irradiation (Fig. 6) UV treatment with 15 uM P12 as compared to 7% and 5% without treatment. We conclude that the defect causing higher susceptibility to the PFA-UV treatment had been corrected in fused cells from patients with disorders ofperoxisome biogenesis belonging to different complementation groups. Similar results were obtained when cells from a patient with X-ALD were fused with those of patient ZSl (complementation group 1). The number of multikaryotic cells increased from 20% to over 50% after PFA treatment (Fig. 6 ). This indicates that different genetic defects cause the increased sensitivity of X-ALD and ZS fibroblasts to PFA-induced UV damage. Fusing X-ALD cells with fibroblasts from complementation Figure 5 . UV resistance of HDG-substituted fibroblasts. Cells from patients with X-ALD (n = 2), ZS (n = 3), and RCDP (n = 3) were incubated with 60 uM HDG for 24 h before P12 incubation. After UV irradiation cell viability was determined as described in Methods. All experiments were done in duplicates, the range ofall results is given. 
P16 Concentration in Media Discussion
Fibroblasts from patients with disorders ofperoxisome biogenesis exhibit decreased resistance to UV irradiation after incubation with PFAs of chain lengths between C0 and C16. This phenomenon can be explained by two facts: First, P12-CoA has been shown to be oxidized in peroxisomes (21) and PFAs accumulate in cells deficient in peroxisomal (3-oxidation. Second, plasmalogens are markedly reduced in these cells. Zoeller et al. (7) presented evidence that the deficiency of plasmalogens is responsible for the increased sensitivity ofChinese hamster ovary cell mutants with defective peroxisome biogenesis which exhibit combined defects ofplasmalogen synthesis and (-oxidation. Supplementation of these cells with HDG, thereby increasing the plasmalogen content, restored resistance to PFA-UV treatment.
Our intention was to separate these two possible mechanisms using fibroblast mutants defective in plasmalogen biosynthesis only (RCDP) and defective peroxisomal (3-oxidation only (bifunctional enzyme deficiency). In both cases mutant cells were more strongly affected by PFA-UV treatment than controls (Fig. 1) . Cells with combined deficiencies (ZS) appeared to be influenced at even lower concentrations of P12. We postulate therefore that the ratio of plasmalogens to radical-producing substances (PFAs) is responsible for rendering cells with peroxisomal defects more susceptible to UV-induced cell damage.
This suggestion is supported by close examination of our data on the intracellular content of PFAs and the sensitivity of cells to UV irradiation (Fig. 1) and the intracellular content of PFAs (Fig. 4) : at a concentration of 10 gM P12 in media, the intracellular amount of P12 was 1.59 nmol/mg protein in control fibroblasts, resulting in survival of 3% after UV irradiation.
In (3- supplementation with HDG protected only plasmalogen-deficient, but not (3-oxidation-deficient cells (Fig. 5) .
Incorporation of P12 into different lipid classes in (3-oxidation-deficient cells (ZS and (3-ox-def) was similar to control (Table 1) . In subcellular fractionation experiments -50% of the fluorescent material was found in particles with a density lower than subcellular organelles. We speculate that these might represent the particles observed in fluorescence microscopy, e.g., lipid droplets.
Although an elevation and defective oxidation of VLCFAs is characteristic for fibroblasts from patients with X-ALD, their sensitivity against UV irradiation and the incorporation of PFAs after incubation with PI0 or P12 was equal to control cells. With P16 however, the PFA incorporation was higher than in controls and the cell damage after UV treatment was comparable to other cell lines with peroxisomal diseases. A defective peroxisomal VLCFA ligase has been proposed to be the cause of X-ALD (22, 23) . Possibly this VLCFA ligase could be specific for PFAs with a chain length higher than P 12. Generally, higher concentrations of P16 in media were required to obtain the same effects than with PI0 or P12. This might either be explained by a poorer solubility and hence a lower bioavailability ofP16 or by a lower rate ofactivation by VLCFA ligase.
Six complementation groups of disorders of peroxisome biogenesis have so far been established by cell fusion experiments (15, 24) . The restoration of plasmalogen biosynthesis and the ability to form peroxisomes as evidenced by the formation ofparticle-bound catalase were used as criteria for successful genetic complementation. Peroxisomal (-oxidation has been measured in fused fibroblasts and complementation experiments using cells from patients with isolated defects in peroxisomal (3-oxidation have been performed (25) . No data exist on whether this pathway is restored in fused cells from patients with ZS and X-ALD.
Our results (Fig. 6) show that fused cells from patients with ZS belonging to different complementation groups (16) -1 | tion to plasmalogen synthesis also the ability to metabolize PFAs is restored. When fibroblasts from patients with ZS belonging to different complementation groups were fused with X-ALD fibroblasts, an increase ofUV resistance was observed. This can be taken as evidence that the genetic defects causing the deficiencies of peroxisomal :-oxidation in ZS and X-ALD are different.
In general, the PFA-UV treatment could be a useful screening test for peroxisomal disorders. Although there are many established methods (2) such as measuring levels or oxidation of VLCFAs, determination of plasmalogen synthesis or dihydroxyacetonephosphate-acyl transferase activity, this test has some advantages. Fibroblasts are more sensitive to PFA-UV treatment when they are deficient either in peroxisomal fl-oxidation or plasmalogen synthesis alone or in a combination of both. The equipment necessary for this test is minimal and a simple UV source can be used after calibration. The incorporation of PFAs can be measured in order to differentiate between defects of 3-oxidation and plasmalogen synthesis.
Another potential application of the method might be the selection of corrected cells in reverse genetics. Fibroblasts with defects in plasmalogen synthesis and/or peroxisomal fl-oxidation could be transfected with a cDNA library, subjected to PFA-UV treatment, and used for isolation ofgene(s) responsible for the defect. A similar procedure has been successfully applied in the characterization of the genetic defect in xeroderma pigmentosum (26, 27) .
Finally, some therapeutic implications should be considered. Provided the lack of plasmalogens is responsible for radical induced cell damage in disorders like ZS and RCDP, substitution of plasmalogens could prevent further damage. Wilson et al. (28) administered ether lipids orally in ZS and achieved a partial normalization ofred blood cell plasmalogen levels. Supplementing RCDP patients with plasmalogens could be even more promising in that only plasmalogen synthesis is deficient in those patients.
